Hongxia Shi

849 total citations
32 papers, 593 citations indexed

About

Hongxia Shi is a scholar working on Hematology, Genetics and Molecular Biology. According to data from OpenAlex, Hongxia Shi has authored 32 papers receiving a total of 593 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hematology, 13 papers in Genetics and 9 papers in Molecular Biology. Recurrent topics in Hongxia Shi's work include Acute Myeloid Leukemia Research (15 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers). Hongxia Shi is often cited by papers focused on Acute Myeloid Leukemia Research (15 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Myeloproliferative Neoplasms: Diagnosis and Treatment (8 papers). Hongxia Shi collaborates with scholars based in China, United Kingdom and Taiwan. Hongxia Shi's co-authors include Xiao‐Jun Huang, Yu Wang, Dai‐Hong Liu, Yu‐Hong Chen, Lan‐Ping Xu, Kai‐Yan Liu, Huan Chen, Yue‐Yun Lai, Ya‐Zhen Qin and Wei Han and has published in prestigious journals such as Blood, Clinical Cancer Research and Molecular Cancer.

In The Last Decade

Hongxia Shi

31 papers receiving 581 citations

Peers

Countries citing papers authored by Hongxia Shi

Since Specialization

Citations

This map shows the geographic impact of Hongxia Shi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hongxia Shi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hongxia Shi more than expected).

Fields of papers citing papers by Hongxia Shi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hongxia Shi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hongxia Shi. The network helps show where Hongxia Shi may publish in the future.

Co-authorship network of co-authors of Hongxia Shi

This figure shows the co-authorship network connecting the top 25 collaborators of Hongxia Shi. A scholar is included among the top collaborators of Hongxia Shi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hongxia Shi. Hongxia Shi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Only FLT3-ITD co-mutation did not have a deleterious effect on acute myeloid leukemia patients with NPM1 mutation, but concomitant with DNMT3A co-mutation or a < 3log reduction of MRD2 predicted poor survival 2024 ·Annals of Hematology ·(unknown), (unknown), Jing Wang, Xiaohong Liu, (unknown), Xiaolu Zhu, Ting Zhao, Qian Jiang, Guo‐Rui Ruan, (unknown), Hongxia Shi, Ying‐Jun Chang, Yu Wang, (unknown), (unknown), Xiaojun Huang, (unknown)	1
2	Treatment of myelofibrosis with refractory anemia with luspatercept: a multicenter Chinese study 2024 ·Annals of Hematology ·Leyu Wang, Liwei Fang, Hongxia Shi, Yinghui Liu, (unknown), Shuxia Guo, (unknown), (unknown), (unknown), Chen Yang, Miao Chen, Bing Han	0
3	Comparison of Safety and Efficacy between Venetoclax Combined with CAG (cytarabine, aclarubicin, G-CSF) Regimen and CAG Regimen Alone in Patients with Relapsed or Refractory Acute Myeloid Leukemia 2023 ·Blood ·(unknown), Ying Wu, Qi Chen, (unknown), Xuying Pei, Jinsong Jia, Jing Wang, Xiao‐Su Zhao, Ying‐Jun Chang, Yue‐Yun Lai, Hongxia Shi, Guo‐Rui Ruan, Ya‐Zhen Qin, Xiaohong Liu, Xiao Jun Huang, Hao Jiang	1
4	Treatment of refractory or relapsed myelodysplastic neoplasms with luspatercept: a multicenter Chinese study 2023 ·Annals of Hematology ·(unknown), (unknown), Xudong Tang, Min Zhang, (unknown), Hongxia Shi, Xiaoqing Ding, Yang Chen, Miao Chen, (unknown)	1
5	Impact of socio-demographic co-variates on prognosis, tyrosine kinase-inhibitor use and outcomes in persons with newly-diagnosed chronic myeloid leukaemia 2021 ·Journal of Cancer Research and Clinical Oncology ·Lu Yu, (unknown), Robert Peter Gale, Ya‐Zhen Qin, Yue‐Yun Lai, Hongxia Shi, (unknown), Xiao‐Jun Huang, Qian Jiang	2
6	Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center 2021 ·Annals of Hematology ·(unknown), Xiaohong Liu, Xiaosu Zhao, Jinsong Jia, Jing Wang, (unknown), Qian Jiang, Ting Zhao, Yu Wang, Xiaohui Zhang, Lan‐Ping Xu, Hongxia Shi, Ying‐Jun Chang, Kai‐Yan Liu, Xiao‐Jun Huang, Ya‐Zhen Qin, Hao Jiang	12
7	Comparable Efficacy and Safety of Generic Imatinib and Branded Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia With a Consideration of Socioeconomic Characteristics: A Retrospective Study From a Single Center 2020 ·Clinical Lymphoma Myeloma & Leukemia ·(unknown), Ya‐Zhen Qin, Yue‐Yun Lai, Hongxia Shi, Xiao‐Jun Huang, Qian Jiang	6
8	High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving Chemotherapy 2018 ·Medical Science Monitor ·Ya‐Zhen Qin, Ting Zhao, Hong‐Hu Zhu, Jing Wang, Jinsong Jia, Yue‐Yun Lai, Xiao‐Su Zhao, Hongxia Shi, Yanrong Liu, Hao Jiang, Xiao‐Jun Huang, Qian Jiang	19
9	Impact of probable interaction of low temperature and ambient fine particulate matter on the function of rats alveolar macrophages 2016 ·Environmental Toxicology and Pharmacology ·Bin Luo, Jiangtao Liu, (unknown), Ting Han, Kai Zhang, Lina Wang, Hongxia Shi, Li Zhang, Ye Ruan, Jingping Niu	27
10	Frequency and allele burden of CALR mutations in Chinese with essential thrombocythemia and primary myelofibrosis without JAK2V617F or MPL mutations 2015 ·Leukemia Research ·Ning Li, (unknown), Robert Peter Gale, Jinlan Li, Ling-Di Li, Xiaosu Zhao, Hao Jiang, Qian Jiang, Bin Jiang, Hongxia Shi, Shanshan Chen, Kai‐Yan Liu, Xiao‐Jun Huang, Guo‐Rui Ruan	15
11	The clinical value of the quantitative detection of four cancer-testis antigen genes in multiple myeloma 2014 ·Molecular Cancer ·Yao Zhang, Bao Li, Jin Lu, Kai‐Yan Liu, Jinlan Li, Ya‐Zhen Qin, Huan Chen, Ling-Di Li, Yuan Kong, Hongxia Shi, Yue‐Yun Lai, Yanrong Liu, Bin Jiang, (unknown), Xiao‐Jun Huang, Guo‐Rui Ruan	8
12	Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: A comprehensive large-scale study from a single Chinese center 2014 ·Leukemia Research ·Ya‐Zhen Qin, Hong‐Hu Zhu, Qian Jiang, Hao Jiang, Leping Zhang, Lan‐Ping Xu, Yu Wang, Yanrong Liu, Yue‐Yun Lai, Hongxia Shi, Bin Jiang, Xiao‐Jun Huang	53
13	NPM1-mutated acute myeloid leukemia of monocytic or myeloid origin exhibit distinct immunophenotypes 2013 ·Leukemia Research ·Yanrong Liu, Hong‐Hu Zhu, Guo‐Rui Ruan, Ya‐Zhen Qin, Hongxia Shi, Yue‐Yun Lai, Yan Chang, Yazhe Wang, Dan Lü, Le Hao, Jinlan Li, Ling-Di Li, Bin Jiang, Xiao‐Jun Huang	28
14	PRAME and WT1 transcripts constitute a good molecular marker combination for monitoring minimal residual disease in myelodysplastic syndromes 2012 ·Leukemia & lymphoma ·Ya‐Zhen Qin, Hong‐Hu Zhu, Yanrong Liu, Yazhe Wang, Hongxia Shi, Yue‐Yun Lai, Lan‐Ping Xu, Dai‐Hong Liu, Qian Jiang, Ling-Di Li, Bin Jiang, Kai‐Yan Liu, Xiao‐Jun Huang	22
15	Imatinib Mesylate Is Superior to Allogeneic Hematopoietic Stem Cell Transplantation As the First-Line Therapy for Patients with Chronic Myeloid Leukemia in the Early Chronic Phase 2011 ·Blood ·Qian Jiang, Lan‐Ping Xu, Dai‐Hong Liu, Kai‐Yan Liu, Bin Jiang, Xiaohui Zhang, Yu Wang, Shanshan Chen, Xiao‐Dong Mo, Xiaosu Zhao, Huan Chen, Yu‐Hong Chen, Wei Han, Hao Jiang, Ya‐Zhen Qin, Yanrong Liu, Yue‐Yun Lai, Hongxia Shi, Meng Lv, Xiao Jun Huang	1
16	Superior Graft-versus-Leukemia Effect Associated with Transplantation of Haploidentical Compared with HLA-Identical Sibling Donor Grafts for High-Risk Acute Leukemia: An Historic Comparison 2010 ·Biology of Blood and Marrow Transplantation ·Yu Wang, Dai‐Hong Liu, Lan‐Ping Xu, Kai‐Yan Liu, Huan Chen, Yu‐Hong Chen, Wei Han, Hongxia Shi, Xiao‐Jun Huang	125
17	Exact feedback linearization control to BUCK converter with constant power loads 2009 ·Hongxia Shi	2
18	HLA-mismatched/haploidentical hematopoietic stem cell transplantation withoutin vitroT cell depletion for chronic myeloid leukemia: Improved outcomes in patients in accelerated phase and blast crisis phase 2008 ·Annals of Medicine ·Xiao‐Jun Huang, (unknown), (unknown), Dai‐Hong Liu, Chen Huan, (unknown), Yu‐Hong Chen, (unknown), Yao Chen, (unknown), Hongxia Shi, (unknown)	45
19	[Studies of treatment strategy and prognosis on acute myeloid leukemia with chromosome 8 and 21 translocation]. 2005 ·PubMed ·Hongxia Shi, Bin Jiang, (unknown), (unknown), Jianfeng Fu, Debing Wang, Dao‐Pei Lu	4
20	Effects of Spirit on Formation of Thrombus in Rats’Tails Caused by Carrageenan 2004 ·Hongxia Shi	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact